A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

University of Miami

Status and phase

Terminated

Phase 2

Phase 1

Conditions

Pain

Prostate Cancer

Treatments

Genetic: GADD45α methylation and expression analysis

Drug: Azacitidine

Drug: Docetaxel

Drug: Prednisone

Drug: Pegfilgrastim

Drug: Filgrastim

Study type

Interventional

Funder types

Other

Identifiers

NCT00503984

SCCC-2006080 (Other Identifier)

20140376 (Other Identifier)

20061143

WIRB-20070344 (Other Identifier)

Details and patient eligibility

About

Azacitidine can reverse clinical resistance to docetaxel through upregulation of Growth Arrest and DNA Damage inducible alpha (GADD45α) and other epigenetically regulated genes.

Full description

Study design A phase I/II clinical trial in patients with hormone refractory metastatic prostate cancer.

Primary objective phase I component of study:

To determine a safe and potentially efficacious phase II dose of azacitidine in combination with docetaxel and prednisone that can be used for the treatment of hormone refractory metastatic prostate cancer.

Primary objective phase II component of study:

To determine the therapeutic efficacy of combined therapy of azacitidine, docetaxel, and prednisone, in the treatment of hormone refractory metastatic prostate cancer. The primary measure of therapeutic efficacy is response, defined as prostate-specific antigen (PSA) response, complete response (CR), or partial response (PR).

Secondary endpoints are toxicity, duration of response, progression-free survival, and overall survival.

Enrollment

22 patients

Sex

Male

Ages

18 to 120 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient who had histologically confirmed adenocarcinoma of the prostate.
Patient must have radiologically documented metastatic disease.
Patients should have received at least 12 weeks of docetaxel chemotherapy or a cumulative docetaxel dose of 300 mg/m2 and have disease progression on docetaxel-based therapy. Patients must have progressed after prior hormonal therapy (e.g. medical or surgical castration) as defined by a castrate level of testosterone (less than 50 ng/mL). If patient underwent medical castration, it must be continued during the study.
Progressive disease may be documented by:
- Non-measurable disease:
  - Serum PSA progression defined as a rise in at least 2 consecutive serum PSA values, each obtained at least 1 week apart and an absolute value greater than 2.0 ng/ml or,
  - Appearance of two or more new lesions on bone scan.
  - Patients with treated epidural lesions and no other epidural progression will be eligible.
- Measurable disease
  - Documented progression of disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria demonstrating at least one visceral or soft tissue metastatic lesion (including new lesion).
  - Nodal or visceral progression will be sufficient for trial entry independent of PSA
  - Only lymph nodes ≥ 2 cm in diameter will be used to assess for a change in size.
  - Previously irradiated lesions, primary prostatic lesion, and bone lesions will be considered non-measurable disease.
Patient is 18 years or older.
Patient had a Karnofsky Performance Status (KPS) of at least 70% or Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2.
Life expectancy of > 6 months.
Patient with adequate organ function as defined as
- Absolute Neutrophils Count greater than 1500 cells/mm3
- Platelets greater than 100,000 cells/mm3
- Hemoglobin greater than 8 g/dL,
- Adequate liver function as documented by:
  - Total Bilirubin </= 1.5 times the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.
  - AST and ALT </= 2.5 ULN. (In determining eligibility the more abnormal of the two values (AST or ALT) should be used.)
- Serum creatinine </= 2.0 mg/dl or </= 1.5 x institutional upper limit of normal.
Male patient must be willing to use an acceptable barrier method for contraception; and must agree not to father a child whilst receiving treatment with Azacitidine and up to six months after last dose.
Patients may have a history of prior malignancy (≥ 5 years prior) provided that the patient is currently disease free and off all therapy for that malignancy. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
Patients must be informed of the investigational nature of the treatment and must give signed written and informed consent.

Exclusion criteria

Patients who have received strontium 89 (metastron®), Samarium 153 (quadramet®) radiation therapy within 8 weeks of enrollment.
Evidence of significant active infection during screening for eligibility.
Patients who have had a psychiatric illness that could potentially interfere with completion of treatment according to protocol.
Patients who had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. There is no wash-out period for patients who received Zytiga.
Patient who had brain metastases.
Patient who had history of allergic reactions attributed to compound or similar chemical or biological composition to azacitidine (Vidaza®) or docetaxel or other drugs formulated with polysorbate 80 or mannitol.
Patient had major surgical procedure within 28 days before Day 1 of treatment.
Hepatic malignancy.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

22 participants in 2 patient groups

Phase 1 - Aza + Doc

Experimental group

Description:

Phase 1 Azacitidine (Aza) and Docetaxel (Doc) with dose escalation/de-escalation design, and Prednisone, with growth factor support; GADD45α methylation and expression analysis, with optional growth factor support (pegfilgrastim/filgrastim).

Treatment: